Combo Rx Boosts Durability of CAR T-Cell Response
San Diego—In hematologic malignancies, chimeric antigen receptor (CAR)-modified T cells will be increasingly combined with other therapeutic strategies, according to multiple studies presented at the 2018 annual meeting of the…
Read More